Diabetic Gastroparesis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Diabetic Gastroparesis
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: - To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo - To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants will go through the following schedule: - Screening period (1-2 visits) - Lead-in period (1 visit) - Will complete a Gastric Emptying Breath Test (GEBT) - Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation - 12-week treatment period (5 visits) - Study drug taken twice daily by mouth - Will complete daily diaries and other PROs as described in protocol - 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: - Drug- CIN-102 Dose 1 - Drug- CIN-102 Dose 2 - Drug- Placebo
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01557296 -
Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis
|
Phase 2 | |
| Withdrawn |
NCT03376399 -
Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms
|
||
| Not yet recruiting |
NCT02264587 -
Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis
|
Phase 4 | |
| Completed |
NCT02289846 -
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
|
Phase 2 | |
| Completed |
NCT03544229 -
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
|
Phase 2 | |
| Recruiting |
NCT04706832 -
Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study
|
N/A | |
| Not yet recruiting |
NCT05584462 -
Gastroparesis in type2 Diabetic Patient
|
||
| Enrolling by invitation |
NCT05812339 -
Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
|
||
| Completed |
NCT02732821 -
G-POEM for Treatment of Refractory Gastroparesis
|
||
| Completed |
NCT01030341 -
Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis
|
N/A | |
| Completed |
NCT02025725 -
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
|
Phase 3 | |
| Completed |
NCT01916460 -
Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients
|
N/A | |
| Completed |
NCT01469286 -
Transcutaneous Electroacupuncture for Gastroparesis
|
Phase 1 | |
| Terminated |
NCT00874133 -
The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis
|
N/A | |
| Completed |
NCT01126034 -
Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention
|
N/A | |
| Recruiting |
NCT05273788 -
Thoracic Neuromodulation for Diabetic Gastroparesis
|
N/A | |
| Suspended |
NCT00470795 -
Acupuncture for Diabetic Gastroparesis
|
Phase 3 | |
| Completed |
NCT00139893 -
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
|
N/A | |
| Recruiting |
NCT04254549 -
Rifaximin in Patients With Diabetic Gastroparesis
|
Phase 2 | |
| Not yet recruiting |
NCT04661215 -
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
|